Doxorubicin, Paclitaxel and Gemcitabine: A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer

T. Ibrahim, M. Fabbri, G. L. Frassineti, W. Zoli, M. Monti, L. Ricotti, D. Amadori

Research output: Contribution to journalArticle

Abstract

Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.

Original languageEnglish
Pages (from-to)488-494
Number of pages7
JournalJournal of Chemotherapy
Volume15
Issue number5
Publication statusPublished - Oct 2003

Fingerprint

gemcitabine
Paclitaxel
Doxorubicin
Breast Neoplasms
Asthenia
Mucositis
Maximum Tolerated Dose
Paresthesia
Myalgia
Alopecia
Therapeutics
Nausea
Diarrhea

Keywords

  • Breast cancer
  • Doxorubicin
  • Gemcitabine
  • Paclitaxel
  • Phase I trial

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Doxorubicin, Paclitaxel and Gemcitabine : A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer. / Ibrahim, T.; Fabbri, M.; Frassineti, G. L.; Zoli, W.; Monti, M.; Ricotti, L.; Amadori, D.

In: Journal of Chemotherapy, Vol. 15, No. 5, 10.2003, p. 488-494.

Research output: Contribution to journalArticle

@article{91a54447ca3a40bba5a49acc5e0f37c0,
title = "Doxorubicin, Paclitaxel and Gemcitabine: A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer",
abstract = "Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.",
keywords = "Breast cancer, Doxorubicin, Gemcitabine, Paclitaxel, Phase I trial",
author = "T. Ibrahim and M. Fabbri and Frassineti, {G. L.} and W. Zoli and M. Monti and L. Ricotti and D. Amadori",
year = "2003",
month = "10",
language = "English",
volume = "15",
pages = "488--494",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Doxorubicin, Paclitaxel and Gemcitabine

T2 - A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer

AU - Ibrahim, T.

AU - Fabbri, M.

AU - Frassineti, G. L.

AU - Zoli, W.

AU - Monti, M.

AU - Ricotti, L.

AU - Amadori, D.

PY - 2003/10

Y1 - 2003/10

N2 - Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.

AB - Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.

KW - Breast cancer

KW - Doxorubicin

KW - Gemcitabine

KW - Paclitaxel

KW - Phase I trial

UR - http://www.scopus.com/inward/record.url?scp=0142154947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142154947&partnerID=8YFLogxK

M3 - Article

C2 - 14598942

AN - SCOPUS:0142154947

VL - 15

SP - 488

EP - 494

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 5

ER -